▶ 調査レポート

世界のカルバペネム系抗生物質市場 2028年:メロペネム、ドリペネム、イミペネム、テビペネム、その他

• 英文タイトル:Global Carbapenem-Based Antibiotics Market Insights, Forecast to 2028

Global Carbapenem-Based Antibiotics Market Insights, Forecast to 2028「世界のカルバペネム系抗生物質市場 2028年:メロペネム、ドリペネム、イミペネム、テビペネム、その他」(市場規模、市場予測)調査レポートです。• レポートコード:QY2207C3468
• 出版社/出版日:QYResearch / 2022年7月11日
• レポート形態:英文、PDF、110ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥725,200 (USD4,900)▷ お問い合わせ
  Multi User¥1,087,800 (USD7,350)▷ お問い合わせ
  Enterprise License¥1,450,400 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症のパンデミックにより、世界のカルバペネム系抗生物質の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にカルバペネム系抗生物質の世界市場のxxx%を占める「メロペネム」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「小売薬局」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
中国のカルバペネム系抗生物質の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのカルバペネム系抗生物質市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパのカルバペネム系抗生物質市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

カルバペネム系抗生物質のグローバル主要メーカーには、ACS Dobfar S.p.A、Iterum Therapeutics plc、DAEWOONG PHARMACEUTICAL CO.,LTD、Aurobindo Pharma Ltd、Gland Pharma Limited、Merck & Co., Inc.、Sumitomo Dainippon Pharma Co., Ltd.、Savior Lifetec、Pfizer Inc.、Spero Therapeuticsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

カルバペネム系抗生物質市場は、種類と用途によって区分されます。世界のカルバペネム系抗生物質市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
メロペネム、ドリペネム、イミペネム、テビペネム、その他

【用途別セグメント】
小売薬局、オンライン薬局、病院薬局

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- カルバペネム系抗生物質製品概要
- 種類別市場(メロペネム、ドリペネム、イミペネム、テビペネム、その他)
- 用途別市場(小売薬局、オンライン薬局、病院薬局)
- 調査の目的
・エグゼクティブサマリー
- 世界のカルバペネム系抗生物質販売量予測2017-2028
- 世界のカルバペネム系抗生物質売上予測2017-2028
- カルバペネム系抗生物質の地域別販売量
- カルバペネム系抗生物質の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別カルバペネム系抗生物質販売量
- 主要メーカー別カルバペネム系抗生物質売上
- 主要メーカー別カルバペネム系抗生物質価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(メロペネム、ドリペネム、イミペネム、テビペネム、その他)
- カルバペネム系抗生物質の種類別販売量
- カルバペネム系抗生物質の種類別売上
- カルバペネム系抗生物質の種類別価格
・用途別市場規模(小売薬局、オンライン薬局、病院薬局)
- カルバペネム系抗生物質の用途別販売量
- カルバペネム系抗生物質の用途別売上
- カルバペネム系抗生物質の用途別価格
・北米市場
- 北米のカルバペネム系抗生物質市場規模(種類別、用途別)
- 主要国別のカルバペネム系抗生物質市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパのカルバペネム系抗生物質市場規模(種類別、用途別)
- 主要国別のカルバペネム系抗生物質市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋のカルバペネム系抗生物質市場規模(種類別、用途別)
- 主要国別のカルバペネム系抗生物質市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米のカルバペネム系抗生物質市場規模(種類別、用途別)
- 主要国別のカルバペネム系抗生物質市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカのカルバペネム系抗生物質市場規模(種類別、用途別)
- 主要国別のカルバペネム系抗生物質市場規模(トルコ、サウジアラビア)
・企業情報
ACS Dobfar S.p.A、Iterum Therapeutics plc、DAEWOONG PHARMACEUTICAL CO.,LTD、Aurobindo Pharma Ltd、Gland Pharma Limited、Merck & Co., Inc.、Sumitomo Dainippon Pharma Co., Ltd.、Savior Lifetec、Pfizer Inc.、Spero Therapeutics
・産業チェーン及び販売チャネル分析
- カルバペネム系抗生物質の産業チェーン分析
- カルバペネム系抗生物質の原材料
- カルバペネム系抗生物質の生産プロセス
- カルバペネム系抗生物質の販売及びマーケティング
- カルバペネム系抗生物質の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- カルバペネム系抗生物質の産業動向
- カルバペネム系抗生物質のマーケットドライバー
- カルバペネム系抗生物質の課題
- カルバペネム系抗生物質の阻害要因
・主な調査結果

Market Analysis and Insights: Global Carbapenem-Based Antibiotics Market
The global Carbapenem-Based Antibiotics market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Meropenem accounting for % of the Carbapenem-Based Antibiotics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Retail Pharmacies segment is altered to an % CAGR throughout this forecast period.
China Carbapenem-Based Antibiotics market size is valued at US$ million in 2021, while the North America and Europe Carbapenem-Based Antibiotics are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Carbapenem-Based Antibiotics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Carbapenem-Based Antibiotics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Carbapenem-Based Antibiotics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Carbapenem-Based Antibiotics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Carbapenem-Based Antibiotics market.
Global Carbapenem-Based Antibiotics Scope and Market Size
Carbapenem-Based Antibiotics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Carbapenem-Based Antibiotics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Meropenem
Doripenemu
Imipenem
Tebipenemu
Others
Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
By Company
ACS Dobfar S.p.A
Iterum Therapeutics plc
DAEWOONG PHARMACEUTICAL CO.,LTD
Aurobindo Pharma Ltd
Gland Pharma Limited
Merck & Co., Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Savior Lifetec
Pfizer Inc.
Spero Therapeutics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Carbapenem-Based Antibiotics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Meropenem
1.2.3 Doripenemu
1.2.4 Imipenem
1.2.5 Tebipenemu
1.2.6 Others
1.3 Market by Application
1.3.1 Global Carbapenem-Based Antibiotics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.3.4 Hospital Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Carbapenem-Based Antibiotics Market Perspective (2017-2028)
2.2 Carbapenem-Based Antibiotics Growth Trends by Region
2.2.1 Carbapenem-Based Antibiotics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Carbapenem-Based Antibiotics Historic Market Size by Region (2017-2022)
2.2.3 Carbapenem-Based Antibiotics Forecasted Market Size by Region (2023-2028)
2.3 Carbapenem-Based Antibiotics Market Dynamics
2.3.1 Carbapenem-Based Antibiotics Industry Trends
2.3.2 Carbapenem-Based Antibiotics Market Drivers
2.3.3 Carbapenem-Based Antibiotics Market Challenges
2.3.4 Carbapenem-Based Antibiotics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Carbapenem-Based Antibiotics Players by Revenue
3.1.1 Global Top Carbapenem-Based Antibiotics Players by Revenue (2017-2022)
3.1.2 Global Carbapenem-Based Antibiotics Revenue Market Share by Players (2017-2022)
3.2 Global Carbapenem-Based Antibiotics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Carbapenem-Based Antibiotics Revenue
3.4 Global Carbapenem-Based Antibiotics Market Concentration Ratio
3.4.1 Global Carbapenem-Based Antibiotics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Carbapenem-Based Antibiotics Revenue in 2021
3.5 Carbapenem-Based Antibiotics Key Players Head office and Area Served
3.6 Key Players Carbapenem-Based Antibiotics Product Solution and Service
3.7 Date of Enter into Carbapenem-Based Antibiotics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Carbapenem-Based Antibiotics Breakdown Data by Type
4.1 Global Carbapenem-Based Antibiotics Historic Market Size by Type (2017-2022)
4.2 Global Carbapenem-Based Antibiotics Forecasted Market Size by Type (2023-2028)
5 Carbapenem-Based Antibiotics Breakdown Data by Application
5.1 Global Carbapenem-Based Antibiotics Historic Market Size by Application (2017-2022)
5.2 Global Carbapenem-Based Antibiotics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Carbapenem-Based Antibiotics Market Size (2017-2028)
6.2 North America Carbapenem-Based Antibiotics Market Size by Type
6.2.1 North America Carbapenem-Based Antibiotics Market Size by Type (2017-2022)
6.2.2 North America Carbapenem-Based Antibiotics Market Size by Type (2023-2028)
6.2.3 North America Carbapenem-Based Antibiotics Market Share by Type (2017-2028)
6.3 North America Carbapenem-Based Antibiotics Market Size by Application
6.3.1 North America Carbapenem-Based Antibiotics Market Size by Application (2017-2022)
6.3.2 North America Carbapenem-Based Antibiotics Market Size by Application (2023-2028)
6.3.3 North America Carbapenem-Based Antibiotics Market Share by Application (2017-2028)
6.4 North America Carbapenem-Based Antibiotics Market Size by Country
6.4.1 North America Carbapenem-Based Antibiotics Market Size by Country (2017-2022)
6.4.2 North America Carbapenem-Based Antibiotics Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Carbapenem-Based Antibiotics Market Size (2017-2028)
7.2 Europe Carbapenem-Based Antibiotics Market Size by Type
7.2.1 Europe Carbapenem-Based Antibiotics Market Size by Type (2017-2022)
7.2.2 Europe Carbapenem-Based Antibiotics Market Size by Type (2023-2028)
7.2.3 Europe Carbapenem-Based Antibiotics Market Share by Type (2017-2028)
7.3 Europe Carbapenem-Based Antibiotics Market Size by Application
7.3.1 Europe Carbapenem-Based Antibiotics Market Size by Application (2017-2022)
7.3.2 Europe Carbapenem-Based Antibiotics Market Size by Application (2023-2028)
7.3.3 Europe Carbapenem-Based Antibiotics Market Share by Application (2017-2028)
7.4 Europe Carbapenem-Based Antibiotics Market Size by Country
7.4.1 Europe Carbapenem-Based Antibiotics Market Size by Country (2017-2022)
7.4.2 Europe Carbapenem-Based Antibiotics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Carbapenem-Based Antibiotics Market Size (2017-2028)
8.2 Asia-Pacific Carbapenem-Based Antibiotics Market Size by Type
8.2.1 Asia-Pacific Carbapenem-Based Antibiotics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Carbapenem-Based Antibiotics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Carbapenem-Based Antibiotics Market Share by Type (2017-2028)
8.3 Asia-Pacific Carbapenem-Based Antibiotics Market Size by Application
8.3.1 Asia-Pacific Carbapenem-Based Antibiotics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Carbapenem-Based Antibiotics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Carbapenem-Based Antibiotics Market Share by Application (2017-2028)
8.4 Asia-Pacific Carbapenem-Based Antibiotics Market Size by Region
8.4.1 Asia-Pacific Carbapenem-Based Antibiotics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Carbapenem-Based Antibiotics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Carbapenem-Based Antibiotics Market Size (2017-2028)
9.2 Latin America Carbapenem-Based Antibiotics Market Size by Type
9.2.1 Latin America Carbapenem-Based Antibiotics Market Size by Type (2017-2022)
9.2.2 Latin America Carbapenem-Based Antibiotics Market Size by Type (2023-2028)
9.2.3 Latin America Carbapenem-Based Antibiotics Market Share by Type (2017-2028)
9.3 Latin America Carbapenem-Based Antibiotics Market Size by Application
9.3.1 Latin America Carbapenem-Based Antibiotics Market Size by Application (2017-2022)
9.3.2 Latin America Carbapenem-Based Antibiotics Market Size by Application (2023-2028)
9.3.3 Latin America Carbapenem-Based Antibiotics Market Share by Application (2017-2028)
9.4 Latin America Carbapenem-Based Antibiotics Market Size by Country
9.4.1 Latin America Carbapenem-Based Antibiotics Market Size by Country (2017-2022)
9.4.2 Latin America Carbapenem-Based Antibiotics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Carbapenem-Based Antibiotics Market Size (2017-2028)
10.2 Middle East & Africa Carbapenem-Based Antibiotics Market Size by Type
10.2.1 Middle East & Africa Carbapenem-Based Antibiotics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Carbapenem-Based Antibiotics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Carbapenem-Based Antibiotics Market Share by Type (2017-2028)
10.3 Middle East & Africa Carbapenem-Based Antibiotics Market Size by Application
10.3.1 Middle East & Africa Carbapenem-Based Antibiotics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Carbapenem-Based Antibiotics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Carbapenem-Based Antibiotics Market Share by Application (2017-2028)
10.4 Middle East & Africa Carbapenem-Based Antibiotics Market Size by Country
10.4.1 Middle East & Africa Carbapenem-Based Antibiotics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Carbapenem-Based Antibiotics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 ACS Dobfar S.p.A
11.1.1 ACS Dobfar S.p.A Company Details
11.1.2 ACS Dobfar S.p.A Business Overview
11.1.3 ACS Dobfar S.p.A Carbapenem-Based Antibiotics Introduction
11.1.4 ACS Dobfar S.p.A Revenue in Carbapenem-Based Antibiotics Business (2017-2022)
11.1.5 ACS Dobfar S.p.A Recent Developments
11.2 Iterum Therapeutics plc
11.2.1 Iterum Therapeutics plc Company Details
11.2.2 Iterum Therapeutics plc Business Overview
11.2.3 Iterum Therapeutics plc Carbapenem-Based Antibiotics Introduction
11.2.4 Iterum Therapeutics plc Revenue in Carbapenem-Based Antibiotics Business (2017-2022)
11.2.5 Iterum Therapeutics plc Recent Developments
11.3 DAEWOONG PHARMACEUTICAL CO.,LTD
11.3.1 DAEWOONG PHARMACEUTICAL CO.,LTD Company Details
11.3.2 DAEWOONG PHARMACEUTICAL CO.,LTD Business Overview
11.3.3 DAEWOONG PHARMACEUTICAL CO.,LTD Carbapenem-Based Antibiotics Introduction
11.3.4 DAEWOONG PHARMACEUTICAL CO.,LTD Revenue in Carbapenem-Based Antibiotics Business (2017-2022)
11.3.5 DAEWOONG PHARMACEUTICAL CO.,LTD Recent Developments
11.4 Aurobindo Pharma Ltd
11.4.1 Aurobindo Pharma Ltd Company Details
11.4.2 Aurobindo Pharma Ltd Business Overview
11.4.3 Aurobindo Pharma Ltd Carbapenem-Based Antibiotics Introduction
11.4.4 Aurobindo Pharma Ltd Revenue in Carbapenem-Based Antibiotics Business (2017-2022)
11.4.5 Aurobindo Pharma Ltd Recent Developments
11.5 Gland Pharma Limited
11.5.1 Gland Pharma Limited Company Details
11.5.2 Gland Pharma Limited Business Overview
11.5.3 Gland Pharma Limited Carbapenem-Based Antibiotics Introduction
11.5.4 Gland Pharma Limited Revenue in Carbapenem-Based Antibiotics Business (2017-2022)
11.5.5 Gland Pharma Limited Recent Developments
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Details
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Carbapenem-Based Antibiotics Introduction
11.6.4 Merck & Co., Inc. Revenue in Carbapenem-Based Antibiotics Business (2017-2022)
11.6.5 Merck & Co., Inc. Recent Developments
11.7 Sumitomo Dainippon Pharma Co., Ltd.
11.7.1 Sumitomo Dainippon Pharma Co., Ltd. Company Details
11.7.2 Sumitomo Dainippon Pharma Co., Ltd. Business Overview
11.7.3 Sumitomo Dainippon Pharma Co., Ltd. Carbapenem-Based Antibiotics Introduction
11.7.4 Sumitomo Dainippon Pharma Co., Ltd. Revenue in Carbapenem-Based Antibiotics Business (2017-2022)
11.7.5 Sumitomo Dainippon Pharma Co., Ltd. Recent Developments
11.8 Savior Lifetec
11.8.1 Savior Lifetec Company Details
11.8.2 Savior Lifetec Business Overview
11.8.3 Savior Lifetec Carbapenem-Based Antibiotics Introduction
11.8.4 Savior Lifetec Revenue in Carbapenem-Based Antibiotics Business (2017-2022)
11.8.5 Savior Lifetec Recent Developments
11.9 Pfizer Inc.
11.9.1 Pfizer Inc. Company Details
11.9.2 Pfizer Inc. Business Overview
11.9.3 Pfizer Inc. Carbapenem-Based Antibiotics Introduction
11.9.4 Pfizer Inc. Revenue in Carbapenem-Based Antibiotics Business (2017-2022)
11.9.5 Pfizer Inc. Recent Developments
11.10 Spero Therapeutics
11.10.1 Spero Therapeutics Company Details
11.10.2 Spero Therapeutics Business Overview
11.10.3 Spero Therapeutics Carbapenem-Based Antibiotics Introduction
11.10.4 Spero Therapeutics Revenue in Carbapenem-Based Antibiotics Business (2017-2022)
11.10.5 Spero Therapeutics Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer